EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Parvovirus B19 Infection in Kidney Transplant Recipients: Clinical Spectrum, Management, and Outcomes in a Large Multicentered Indian Cohort

Priti Meena iD, Vijaychander Bukka iD, Vinant Bhargava, Vivek Pathak, Umapati Hegde, Vishal Singh iD, Ashay Shingare iD, Sanjiv Jasuja iD, Vishwanath Siddini, Swarnalatha Guditi, Anil Bhalla, Sandip Panda und 9 weitere

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70174 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Priti Meena und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India. Hauptthemen laut MEDLINE: Kidney Transplantation, Parvovirus B19, Human, Parvoviridae Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parvovirus B19 (PVB19) is a clinically important cause of refractory anemia in kidney transplant recipients (KTRs). Data from low‐ and middle‐income settings remain scarce despite high transplant volumes. This study evaluated the clinical spectrum, management practices, and outcomes of PVB19 infection across major transplant programs in India.

Methods

We conducted a retrospective multicenter cohort study across 14 tertiary transplant centers. All KTRs with PCR‐confirmed PVB19 infection and complete clinical data were included. Clinical features, bone marrow findings, immunosuppressive (IS) adjustments, intravenous immunoglobulin (IVIG) use, and patient and graft outcomes were analyzed.

Results

A total of 135 KTRs were identified. Median time to infection was 11 weeks posttransplant. Anemia was universal, not frequently accompanied by leukopenia (17.7%) or thrombocytopenia (14.8%). Bone marrow examinations ( n = 34) demonstrated giant proerythroblasts or pure red cell aplasia. IS reduction was implemented in all patients; most commonly, complete MMF withdrawal (61.5%). IVIG was administered to 90% (median cumulative dose 100 g). Overall, 97% achieved hematologic recovery, with a median response time of 20 days. Recurrence occurred in 4.4%. At a median follow‐up of 18 months, graft survival was 92.6%; graft loss ( n = 10) was primarily due to antibody‐mediated rejection, and no deaths were attributable to PVB19.

Conclusions

PVB19 infection represents an important consideration in the differential diagnosis of early posttransplant anemia in KTRs. Timely PCR testing and pragmatic treatment strategies can achieve favorable hematologic and graft outcomes in resource‐constrained settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationParvovirus B19, HumanParvoviridae InfectionsHumansIndiaRetrospective StudiesMaleFemaleAdultImmunoglobulins, IntravenousMiddle AgedImmunosuppressive AgentsTreatment OutcomeTransplant RecipientsAnemiaYoung Adult

Stichwörter der Autor:innen

Indian cohortkidney transplant recipientsmulticenterparvovirus B19 infection

Substanzen

Immunoglobulins, IntravenousImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nephrology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
  • Department of Nephrology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
  • Department of Nephrology, Sir Ganga Ram Hospital, New Delhi, India.
  • Department of Nephrology, Kovai Kidney Center, Coimbatore, Tamil Nadu, India.
  • Muljibhai Patel Urological Hospital (MPUH), Nadiad, Gujarat, India.
  • Army Hospital (R&R), New Delhi, India.

ORCID-Profile: Priti Meena, Vijaychander Bukka, Vishal Singh, Ashay Shingare, Sanjiv Jasuja

Zitieren

APA

Meena, P., Bukka, V., Bhargava, V., Pathak, V., Hegde, U., Singh, V., Shingare, A., Jasuja, S., Siddini, V., Guditi, S., Bhalla, A., Panda, S., Fernando, M. E., Canchi, A., Thanikachalam, D. K., Godhani, U., Grover, R., Kumari, P. R., Bahadur, M. M., …, & Kute, V. (2026). Parvovirus B19 Infection in Kidney Transplant Recipients: Clinical Spectrum, Management, and Outcomes in a Large Multicentered Indian Cohort. Transplant Infectious Disease. https://doi.org/10.1111/tid.70174

Vancouver

Meena P, Bukka V, Bhargava V, Pathak V, Hegde U, Singh V, et al. Parvovirus B19 Infection in Kidney Transplant Recipients: Clinical Spectrum, Management, and Outcomes in a Large Multicentered Indian Cohort. Transplant Infectious Disease. 2026. doi:10.1111/tid.70174

BibTeX
@article{Meena2026,
  author = {Meena, Priti and Bukka, Vijaychander and Bhargava, Vinant and Pathak, Vivek and Hegde, Umapati and Singh, Vishal and Shingare, Ashay and Jasuja, Sanjiv and Siddini, Vishwanath and Guditi, Swarnalatha and Bhalla, Anil and Panda, Sandip and Fernando, M Edwin and Canchi, Arvind and Thanikachalam, Dinesh Kumar and Godhani, Umesh and Grover, Rajat and Kumari, Prity Rai and Bahadur, M M and Tambi, Priyash and Kute, Vivek},
  title = {Parvovirus B19 Infection in Kidney Transplant Recipients: Clinical Spectrum, Management, and Outcomes in a Large Multicentered Indian Cohort},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70174}
}
Kostenlos starten →